Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin.

Scientific reports - 23 Jun 2020

Lamsfus-Calle Andrés, Daniel-Moreno Alberto, Antony Justin S, Epting Thomas, Heumos Lukas, Baskaran Praveen, Admard Jakob, Casadei Nicolas, Latifi Ngadhnjim, Siegmund Darina M, Kormann Michael S D, Handgretinger Rupert, Mezger Markus

Abstract excerpt

β-hemoglobinopathies are caused by abnormal or absent production of hemoglobin in the blood due to mutations in the β-globin gene (HBB). Imbalanced expression of adult hemoglobin (HbA) induces strong anemia in patients suffering from the disease. However, individuals with natural-occurring mutations in the HBB cluster or related genes, compensate this disparity through γ-globin expression and subsequent fetal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Antigens, CD34

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Fetal Hemoglobin

Share to gamma-Globins

Share to Gene Editing

Share to Kruppel-Like Transcription Factors

Share to Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 32576837
DOI: 10.1038/s41598-020-66309-x
PMCID: PMC7311455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin.PMID 32576837Read ↗

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read ↗

A Review of Gene Therapies for HemoglobinopathiesSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobinSemantic proximity Read ↗

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 <sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read ↗

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell diseaseSemantic proximity Read ↗

Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia diseaseSemantic proximity Read ↗

Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donorsSemantic proximity Read ↗

Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysisSemantic proximity Read ↗

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read ↗

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-ThalassemiaSemantic proximity Read ↗

Targeted Therapeutic Strategies for Fetal Hemoglobin InductionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.